Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-label, Randomized, Controlled Study of Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With High-risk Early-stage or Locally Advanced HER2-negative Breast Cancer

NCT05673629 is registered in ClinicalTrials.gov with Beijing Biostar Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT05673629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05673629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-label, Randomized, Controlled Study of Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With High-risk Early-stage or Locally Advanced HER2-negative Breast Cancer
Lead sponsor
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
May 30, 2023
Completion date
December 31, 2025
Enrollment
552 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer